Annual FCF
$134.19 M
+$230.86 M+238.81%
December 31, 2023
Summary
- As of February 7, 2025, TRDA annual free cash flow is $134.19 million, with the most recent change of +$230.86 million (+238.81%) on December 31, 2023.
- During the last 3 years, TRDA annual FCF has risen by +$162.08 million (+581.17%).
- TRDA annual FCF is now at all-time high.
Performance
TRDA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$24.91 M
-$63.69 M-164.21%
September 30, 2024
Summary
- As of February 7, 2025, TRDA quarterly free cash flow is -$24.91 million, with the most recent change of -$63.69 million (-164.21%) on September 30, 2024.
- Over the past year, TRDA quarterly FCF has increased by +$1.03 million (+3.99%).
- TRDA quarterly FCF is now -112.35% below its all-time high of $201.73 million, reached on March 31, 2023.
Performance
TRDA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$17.46 M
+$1.03 M+5.59%
September 30, 2024
Summary
- As of February 7, 2025, TRDA TTM free cash flow is -$17.46 million, with the most recent change of +$1.03 million (+5.59%) on September 30, 2024.
- Over the past year, TRDA TTM FCF has dropped by -$128.63 million (-115.71%).
- TRDA TTM FCF is now -113.01% below its all-time high of $134.19 million, reached on December 31, 2023.
Performance
TRDA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
TRDA Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +238.8% | +4.0% | -115.7% |
| 3 y3 years | +581.2% | +11.1% | +81.9% |
| 5 y5 years | +1273.9% | +11.1% | +81.9% |
TRDA Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +238.8% | -112.3% | +32.0% | -113.0% | +81.9% |
| 5 y | 5-year | at high | +238.8% | -112.3% | +32.0% | -113.0% | +81.9% |
| alltime | all time | at high | +238.8% | -112.3% | +32.0% | -113.0% | +81.9% |
Entrada Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$24.91 M(-164.2%) | -$17.46 M(-5.6%) |
| Jun 2024 | - | $38.79 M(-247.2%) | -$18.50 M(-80.3%) |
| Mar 2024 | - | -$26.36 M(+428.3%) | -$93.90 M(-170.0%) |
| Dec 2023 | $134.19 M(-238.8%) | -$4.99 M(-80.8%) | $134.19 M(+20.7%) |
| Sep 2023 | - | -$25.94 M(-29.2%) | $111.17 M(+2.2%) |
| Jun 2023 | - | -$36.61 M(-118.1%) | $108.81 M(-14.1%) |
| Mar 2023 | - | $201.73 M(-820.2%) | $126.64 M(-231.0%) |
| Dec 2022 | -$96.67 M | -$28.01 M(-1.0%) | -$96.67 M(+6.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$28.29 M(+50.6%) | -$90.52 M(+17.4%) |
| Jun 2022 | - | -$18.78 M(-13.0%) | -$77.11 M(+13.8%) |
| Mar 2022 | - | -$21.59 M(-1.3%) | -$67.78 M(+22.3%) |
| Dec 2021 | -$55.44 M(+98.8%) | -$21.86 M(+46.9%) | -$55.44 M(+65.1%) |
| Sep 2021 | - | -$14.88 M(+57.4%) | -$33.58 M(+79.6%) |
| Jun 2021 | - | -$9.45 M(+2.3%) | -$18.70 M(+102.3%) |
| Mar 2021 | - | -$9.24 M | -$9.24 M |
| Dec 2020 | -$27.89 M(+144.0%) | - | - |
| Dec 2019 | -$11.43 M | - | - |
FAQ
- What is Entrada Therapeutics annual free cash flow?
- What is the all time high annual FCF for Entrada Therapeutics?
- What is Entrada Therapeutics annual FCF year-on-year change?
- What is Entrada Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly FCF year-on-year change?
- What is Entrada Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Entrada Therapeutics?
- What is Entrada Therapeutics TTM FCF year-on-year change?
What is Entrada Therapeutics annual free cash flow?
The current annual FCF of TRDA is $134.19 M
What is the all time high annual FCF for Entrada Therapeutics?
Entrada Therapeutics all-time high annual free cash flow is $134.19 M
What is Entrada Therapeutics annual FCF year-on-year change?
Over the past year, TRDA annual free cash flow has changed by +$230.86 M (+238.81%)
What is Entrada Therapeutics quarterly free cash flow?
The current quarterly FCF of TRDA is -$24.91 M
What is the all time high quarterly FCF for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly free cash flow is $201.73 M
What is Entrada Therapeutics quarterly FCF year-on-year change?
Over the past year, TRDA quarterly free cash flow has changed by +$1.03 M (+3.99%)
What is Entrada Therapeutics TTM free cash flow?
The current TTM FCF of TRDA is -$17.46 M
What is the all time high TTM FCF for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM free cash flow is $134.19 M
What is Entrada Therapeutics TTM FCF year-on-year change?
Over the past year, TRDA TTM free cash flow has changed by -$128.63 M (-115.71%)